EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.

ABSTRACT:

Background

Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response.

Patients and methods

Patients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with <10% viable tumour were allocated to MAP or MAP followed by pe

SUBMITTER: Whelan JS 

PROVIDER: S-EPMC4304379 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature